Back to Search
Start Over
The most important facilitators and barriers to the use of Health Technology Assessment in Canada
- Source :
- Journal of Medical Economics, 24(1), 846-856. Routledge/Taylor & Francis Group
- Publication Year :
- 2021
- Publisher :
- Routledge/Taylor & Francis Group, 2021.
-
Abstract
- Background Health Technology Assessment (HTA), which can support public drug reimbursement decisions will play a core function in the planned national Pharmacare program in Canada. To address existing barriers to the use of HTA, these must be ranked in order of priority. The goal of this study was to access the relative importance of known facilitators and barriers to the use of HTA in the context of the Canadian health care system, with attention to differences between regions and stakeholder groups. Methods We used the best-worst scaling object case approach to elicit a quantitative ranking of a list of 20 facilitators and 22 barriers. A sample of 68 Canadian HTA stakeholders, including members of expert committees, decision/policymakers, researchers/academics, and others participated in the study. Their task was to identify the most important and the least important item in 12 sub-sets of five facilitators and 14 sub-sets of five barriers. Findings Relative Importance Scores derived via hierarchical Bayes analysis revealed relations, engagement, and contact between stakeholders as most important on both the barrier and facilitator sides. Other top-ranked facilitators included the availably of credible and relevant research. Other top-ranked barriers included inconsistencies in the evidence and limited generalizability. The availability of HTA guidelines did not rank highly on either side. The main limitation of the study was the challenge with reaching the relevant respondents; this was mitigated by involving the national HTA agency in the research. Conclusion Canadian stakeholders consider the relationships within the HTA network among the most important. Policies should focus on strengthening these relationships. Future research should focus on the connectivity and distribution of knowledge and power within the HTA network.
- Subjects :
- Canada
Technology Assessment, Biomedical
Drug reimbursement
Decision Making
PREFERENCES
ECONOMIC-EVALUATION
Best–worst scaling
03 medical and health sciences
0302 clinical medicine
Humans
Medicine
best-worst scaling
Core function
business.industry
relative importance scores
030503 health policy & services
Health Policy
food and beverages
Health technology
Health Technology Assessment
HTA
Bayes Theorem
selection of pharmaceuticals
DECISION-MAKING PROCESSES
Risk analysis (engineering)
030220 oncology & carcinogenesis
Economic evaluation
0305 other medical science
business
Delivery of Health Care
Canadian Pharmacare
Subjects
Details
- Language :
- English
- ISSN :
- 1941837X and 13696998
- Volume :
- 24
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Journal of Medical Economics
- Accession number :
- edsair.doi.dedup.....afa357fdf139e07598423b8bb95ed884